February 27, 2023
Alliance A042001: Randomized phase II CD22+ B-cell ALL (ino + mini-hyper-CVD vs. dose adjusted hyper-CVAD) for patients over age 50
Marlise Luskin, MD, MSCE , of Dana-Farber Cancer Institute, leads Alliance A042001 - a phase II trial that compares the combination of inotuzumab ozogamicin and chemotherapy to the usual chemotherapy in treating patients with B-cell acute lymphoblastic leukemia or B-cell
The Alliance extends its deepest appreciation and gratitude to Michael J. Morris, MD (Memorial Sloan Kettering Cancer Center) as he steps down as Chair of the Alliance Genitourinary Committee. Over the past 10 years, Dr. Morris has guided the Alliance GU Committee with his endless, dedicated service and mentorship. The field of GU oncology has expanded dramatically in recent years, and Alliance researchers
February 13, 2023
The Alliance Board of Directors is pleased to announce the appointment of Isabelle Bedrosian, MD, to the position of Director of the Alliance Program for Procedure-Based Therapy. Dr. Bedrosian is the Medical Director of the Nellie B. Connally Breast Center and Professor of Breast Surgical Oncology at The University of Texas MD Anderson Cancer Center.
Dr. Bedrosian has a long history of success
